Abstract: The present study aimed to evaluate the levels of soluble receptor for advanced glycation end products (sRAGE) and tumor necrosis factor-α (TNF-α) in serum and gingival crevicular fluid (GCF) in chronic periodontitis (CP) patients with and without type 2 diabetes mellitus (T2DM). A total of 70 subjects were divided into four groups: group 1 (n = 15; subjects with healthy periodontium); group 2 (n = 20; CP patients); group 3 (n = 20; CP patients with T2DM); and group 4 (n = 15; CP patients without T2DM). The serum and GCF levels of human sRAGE and TNF-α were assessed using enzyme-linked immunosorbent assay and correlated with clinical parameters, including probing depth, gingival index and clinical attachment level. Both sRAGE and TNF-α levels varied with the inflammatory state of the patient; the highest levels of sRAGE were seen in group 1, whereas the lowest levels in group 3 (P < 0.05). Conversely, TNF-α levels were found to be the highest in group 3 and lowest in group 1 (P < 0.05). Thus, human sRAGE and TNF-α can be considered as possible GCF and serum markers of inflammatory activity in CP and T2DM. (J Oral Sci 58, 547-553, 2016)
Introduction
Chronic periodontitis (CP) is an inflammatory disease of multi-factorial origin which causes the destruction of supporting tooth structures by releasing a broad array of inflammatory mediators (1) . Activation of the inflammatory-immune system by periodontal pathogens leads to chronic inflammation, causing progressive destruction of the connective tissues and resorption of the alveolar bone; if left untreated, it finally leads to tooth loss (2, 3) . The extent of inflammation and destruction of the periodontal tissues can be evaluated by analyzing the components of the gingival crevicular fluid (GCF) because several inflammatory and immune mediators implicated in periodontal destruction have been established in GCF (4, 5) . Diabetes mellitus (DM) is a complex metabolic disorder characterized by abnormal sugar, fat, and protein metabolism (6) . Another feature of this disease is the precipitation of hyperglycemia due to disruption in insulin production or defects in its action, which may lead to various systemic complications (6) . The risk of developing severe periodontitis is two-to four-fold higher in diabetic subjects than in those without diabetes (7) . In 1993, Loe considered periodontitis as the sixth complication of diabetes (8) . The global epidemic of Type 2 DM (T2DM) is increasing rapidly and will affect over 300 million people by the year 2025 (9) . RAGE, the receptor for advanced glycation end products (AGEs), is a multi-ligand receptor of the immunoglobulin superfamily of cell surface molecules; it is synthesized by the nonenzymatic glycation and oxidation of proteins (10, 11) . AGEs is a heterogeneous class of structures, and N ε (carboxymethyl) lysine (CML) adducts, the most prevalent of the AGEs, are signal transduction ligands of RAGE (12) . sRAGE is a decoy receptor that could act as a competitive inhibitor of the cascade of signaling pathways, and is induced by the interaction of AGEs with RAGE (13). Basta et al, concluded that the decrease in sRAGE was associated with T2DM and hyperglycemia, and was negatively correlated with S100A12 protein (14) . Studies involving experimental animal models of streptozotocin-induced diabetes and genetically manipulated mice treated with sRAGE have shown that it prevents cell-bound RAGE signaling (15) (16) (17) . Clinical trials conducted in humans have shown an inverse relationship wherein increases in the levels of endogenous sRAGE may be associated with a lower incidence of hypertension (18) , arthritis (19) , and coronary artery disease (20) . The expression levels of tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine produced by activated macrophages, dendritic cells, mast cells, and T lymphocytes (21) , were found to be increased in CP and rheumatoid arthritis (RA) and decreased after anti-TNF-α therapy (22) . Unopposed interactions between AGEs and RAGE lead to increased levels of TNF-α in subjects with decreased serum levels of sRAGE via an increase in NF-κB activation (23) .
To date, to best of our knowledge, this is the first study to investigate the levels of human sRAGE in GCF and serum, and its association with TNF-α levels in CP patients with and without T2DM.
Materials and Methods
A cross-sectional study of 3-month duration comprising 70 subjects aged 25-45 years (male:female ratio, 1:1) was conducted from October 2014 to January 2015. Patients with chronic periodontitis were selected according to the criteria of the 1999 International Workshop for Classification of Periodontal Diseases and Conditions (24) . All participants were verbally informed, and written informed consent was obtained before clinical examination and sample collection. The study protocol was approved by the Institutional Ethical Committee and Review Board of Government Dental College and Research Institute (GDCRI) (GDCRI/ACM/PG/PhD/2/2014-2015). Those with T2DM were recruited from the outpatient section of the Department of Medicine, Victoria Hospital, Bangalore, India, whereas the remaining patients were enlisted from the outpatient section of the Department of Periodontology, GDCRI, Bangalore, India. (27) , and glycated hemoglobin levels (HbA1c) (28) . Well-controlled T2DM subjects were classified according to the American Diabetic Association (ADA) guidelines in 2011. Patients who smoked tobacco in any form, had aggressive periodontitis, RA, hypertension, pregnancy, gross oral pathology, or tumors as well as other systemic diseases that could affect the periodontium were excluded from the study. In addition, those who had received anti-inflammatory and/or antibiotic medications for the past 6 months, or periodontal therapy in the past year were also excluded.
Inclusion-exclusion criteria

Subject grouping
The subjects were categorized into four groups based on the GI, PD, CAL, radiographic evidence of bone loss, and HbA1C. Group 1 (healthy subjects) comprised 15 participants with clinically healthy periodontium; GI = 0 (absence of clinical inflammation), CAL = 0, and PD ≤ 3 mm, and no radiographic evidence of bone loss. Group 2 (CP without T2DM) comprised 20 participants (GI > 1, CAL ≥ 3 mm, and PD ≥ 5 mm) with evidence of bone loss on the radiograph. Group 3 (T2DM along with CP) comprised 20 participants (GI > 1, CAL ≥ 3 mm, PD ≥ 5 mm, and HbA1c ≤ 7%) with radiographic evidence of bone loss. Group 4 (T2DM without chronic periodontitis) consisted of 15 diabetic patients with clinically healthy periodontium (GI = 0, PD ≤ 3 mm, CAL = 0, and HbA1c ≤ 7%) and no radiographic evidence of bone loss.
Clinical evaluation of subjects
Group allocation and sample site selection was performed by the chief coordinator (ARP) of this study. Thorough case history was taken from each participant. The clinical parameters were evaluated by a calibrated examiner (SS) using a periodontal probe (University of North Carolina-15 periodontal probe, Hu-Friedy, Chicago, IL, USA). Radiographic analysis was performed to determine bone loss dichotomously (presence or absence). Full mouth intraoral periapical radiographs (IOPA) were taken from all subjects and standardized using the long cone paralleling technique. Customized bite blocks with acrylic resin were developed under standard conditions. The same examiner (SS) evaluated the radiograph and also collected the serum and GCF samples from the patients during the same appointment.
Site selection
Two sites were selected on the basis of CAL, inflammatory sign, and radiographic evidence of bone loss for sampling in subjects belonging to groups 2 and 3. The mesio-buccal area of the left maxillary first molar was predetermined; in the absence of which, the maxillary right first molar was sampled in order to standardize site selection and also to prevent saliva contamination in subjects belonging to groups 1 and 4. One of the two sites selected per subject was used for sRAGE and the other for TNF-α analysis.
GCF collection
The selected site was swabbed with cotton to remove debris and then isolated with sterile cotton rolls and air dried. Supragingival plaque, if present, was removed gently using a universal curette (Universal Gracey Curette #4R/4L, Hu-Friedy) so as to obviate contamination of the paper strips (periopaper, Ora Flow Inc., Amityville, NY, USA). A paper strip was then placed gently for 60 s at the entrance of the gingival sulcus until mild resistance was perceived (29) , utmost care was taken to circumvent mechanical injury. GCF volume of each paper strip was calibrated by a device (Periotron 8000, ProFlow Inc., Amityville, NY, USA). Those contaminated by saliva or blood were excluded. Two GCF absorbed strips (premarked with the name of the biomarker) per site from each subject were pooled, transferred to microcentrifuge tubes containing 400 μL of phosphate-buffered saline (PBS), and stored at −70°C until processing. Scaling and root planing were performed on the CP patients by the operator (DK) after biofluid collection in the same appointment.
Serum collection
Blood (2 mL) was collected from the antecubital fossa by venipuncture using a 20-gauge needle after disinfecting the site. The sample was then immediately transferred to the laboratory, where it was left undisturbed for 1 h at room temperature to facilitate clot formation. Subsequently, the sample was centrifuged at 1,000 rpm for 15 min to separate the serum component, which was then stored at −70°C.
Human sRAGE and TNF-α analysis
The GCF sample was homogenized for 30 s and centrifuged for 5 min at 1,500 g. The elute was then used for the detection of sRAGE and TNF-α using the human sRAGE ELISA kit (ABO Swiss Co. Ltd, Shanghai, China) and TNF-α ELISA kit (RayBiotech, Inc., Delhi, India), respectively. Color development was quantified using an ELISA reader. Optical density was read at 450 nm after the addition of the stop solution. sRAGE and TNF-α concentrations were calculated by dividing the amount of sRAGE or TNF-α by the total volume of the respective samples (pg/mL).
Statistical analysis
Statistical analysis was done using SPSS statistical software (SPSS version 18.0, Chicago, IL, USA). Power calculations were performed initially, and 12 subjects per group were required to achieve 90% power and detect mean differences between the groups. Analysis of variance (ANOVA) was carried out to compare GCF and serum sRAGE and TNF-α levels between the groups. Associations between sRAGE and TNF-α concentrations and the clinical parameters were evaluated using Pearson's correlation coefficient. Intra-group correlations between serum and GCF concentrations of sRAGE and TNF-α were also performed using this correlation coefficient. Scheff's test was used to conduct pair-wise comparisons between groups for sRAGE and TNF-α concentrations in GCF and serum. P values < 0.05 were considered statistically significant. The mean intraexaminer standard deviation of differences in repeated PD and CAL measurements was obtained using single passes of measurements (correlation coefficients between duplicate measurements; r = 0.95).
Results
Descriptive statistical analysis is represented in Table 1 . Mean sRAGE concentrations in both GCF and serum were the highest in group 1 (690.74 ± 68.38, 732.88 ± 68.97), followed by group 2 (607.56 ± 84.40, 626.565 ± 84.54), group 4 (536.88 ± 78.83, 555.99 ± 83.53), and the lowest in group 3 (442.425 ± 72.88, 460.23 ± 81.23). On the other hand, the GCF and serum TNF-α levels were lowest in group 1 (1.57 ± 0.621, 2.13 ± 0.86), followed by group 2 (5.32 ± 0.74, 5.46 ± 0.80), group 4 (6.3 ± 0.51, 6.57 ± 0.59), and highest in group 3 (7.365 ± 1.072, 7.95 ± 1.29).
Statistically significant negative correlations, as determined by Pearson's correlation coefficient test, were observed between the serum and GCF levels of sRAGE and TNF-α ( Table 2 ). The GCF and serum levels of sRAGE and TNF-α were positively correlated with clinical parameters (PD and CAL) as shown in Table 3 ; the correlations were statistically significant in all the groups (P < 0.05). Tables 4 and 5 represent statistically significant pair-wise correlations between the groups for sRAGE and TNF-α concentrations in GCF and serum, respectively.
Discussion
This study aimed to evaluate the levels of sRAGE and TNF-α in GCF and serum in CP patients with and without T2DM. The results of the study showed reduced sRAGE and increased TNF-α levels in the GCF and serum of CP patients with T2DM. The expression of sRAGE and TNF-α in localized inflammatory conditions (such as CP) and systemic conditions (like T2DM) suggests that both sRAGE and TNF-α can be considered as biomarkers for inflammatory periodontal disease and T2DM. Basta et al reported decreased levels of sRAGE in diabetic subjects and demonstrated their correlation with glycemic control, homeostatic model assessment, and the inflammatory marker, C-reactive protein. Basta et al. also documented an inverse association between plasma levels of sRAGE and S100A12, a pertinent proinflammatory molecule that was strongly linked with RAGE signaling (14) .
In a previous study, we showed an increase in GCF and serum levels of both S100A12 or En-RAGE and hs-CRP in patients with CP, and in those with CP and T2DM rather than in healthy subjects; we concluded that both S100A12 and hs-CRP are correlated and can be considered as potential biomarkers for inflammatory periodontal disease and T2DM (30) . Recent studies have shown reduced levels of sRAGE in obesity and obesity-associated T2DM, and have demonstrated its .01* -*P < 0.05; (-) Showed no correlation between sRAGE and TNF-α as groups 1 and 2 contain clinically healthy periodontium with CAL = 0, GI = 0.
inverse correlation with concentrations of calprotectin and TNF-α (31). RAGE is an important pathogenic factor for the development of long-term renal changes in T2DM (32) , and a number of studies have suggested that the administration of sRAGE exerts a protective effect against diabetic complications (16, 32, 33) . The AGE-RAGE interaction in macrophages can lead to increased levels of pro-inflammatory cytokines like TNF-α and interleukin-1β (IL-1β) (34) . Elevated levels of TNF-α affect insulin sensitivity via direct and indirect mechanisms, thereby worsening the diabetic status (35) (36) (37) , which may in turn lead to further periodontal breakdown (35) (36) (37) . Thus, TNF-α plays a major role in the vicious cycle linking periodontal disease and diabetes. The precise reason for the low levels of sRAGE in diabetic patients is unknown. It was postulated that the synthesis of sRAGE can be inhibited directly by hyperglycemia or by increased levels of cytokine and/or hyperglycemiainduced AGEs (14) . Furthermore, lower levels of sRAGE can also be caused due to increased clearance of AGE/ sRAGE complexes (38) .
The mean GCF and serum concentrations of TNF-α in patients belonging to the CP group with T2DM was greater than those seen in the T2DM group. Thus, the mean concentration of TNF-α was elevated in GCF and serum with the progression of the CP, thereby worsening glycemic control. The results of the present study showed that the levels of TNF-α in GCF and serum were significantly inversely correlated with sRAGE in CP. This might indicate some element of systemic inflammation along with localized periodontal inflammation in some subjects. Shaw et al. (39) in a study dealing with biomarkers of progression of chronic obstructive pulmonary disease found the emphysema severity was associated with increased adiponectin and reduced sRAGE, whereas exacerbations and mortality were associated with increased CRP, fibrinogen, leukocyte count, IL-6, IL-8, and TNF-α, thus indicating the inverse relationship between sRAGE and TNF-α in chronic inflammatory diseases. To the best of our knowledge, this is the first study to evaluate and correlate sRAGE and TNF-α levels in CP patients with and without T2DM. One limitation of this cross-sectional study is the small sample size. Further interventional and longitudinal studies involving larger sample sizes should be carried out to ascertain the findings of the study and to better understand the role of these inflammatory biomarkers in CP and T2DM.
Within the limitations of the study, sRAGE and TNF-α can be considered as potential biomarkers of periodontal disease. Low sRAGE and high TNF-α levels in CP patients with T2DM may signify the occurrence of an active inflammatory process both locally in periodontal tissues and systemically, thus suggesting a correlation between glycemic control and periodontitis. These biomarkers can therefore be valuable in detecting highrisk individuals with periodontal disease, and systemic diseases like diabetes. Further longitudinal prospective studies must be carried out to confirm these findings and to understand the possible roles of sRAGE and TNF-α in the pathogenesis of periodontitis and diabetes.
